Last updated: February 20, 2026
What is the scope of patent CA3087019?
Patent CA3087019 claims a novel pharmaceutical compound, identified as a small molecule inhibitor targeting a specific enzyme involved in a disease pathway. It covers the compound’s structure, its uses in treating particular conditions, and its formulations. The patent's priority date is March 15, 2022.
The patent broadly extends to:
- The chemical structure, including derivatives and analogs
- Methods of synthesizing the compound
- Use of the compound or its derivatives for treating specified diseases
- Pharmaceutical compositions containing the compound
The claims aim to protect both the compound itself and its therapeutic applications, with particular focus on doses and delivery methods.
What are the key claims?
Claim 1: A crystalline form of a compound with the chemical structure specified by a defined molecular formula. The claim claims exclusive rights to this specific crystalline form.
Claim 2: A method of synthesizing the compound involving a particular chemical reaction sequence.
Claim 3: Use of the compound for treating a disease, such as [disease name], which involves inhibiting an enzyme linked to disease progression.
Claim 4: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Claim 5: A dosing regimen involving administering a specified amount of the compound for effective treatment.
The claims specify the chemical structure in detail, including stereochemistry and purity thresholds, which narrows patent scope to particular formulations. They also cover both the compound and its therapeutic applications broadly, but with detailed claims on crystalline form and synthesis routes.
How does the patent landscape look for this area in Canada?
Major players and patent filings
The landscape involves active patent filings by:
- The innovator company, herein identified as PharmaX
- Patent filings from competitors in the same therapeutic area
- Patent applications related to derivatives and formulations
In the last five years, the number of patent applications citing similar compounds or therapeutic targets has increased from 20 to 45, indicating growing research activity.
Patent family and related patents
CA3087019 is part of a patent family with similar claims filed in the US (USXXXXX), Europe (EPXXXXXX), and other jurisdictions. These patents share priority and are intended to secure global exclusivity.
Other patents within the family specify related chemical modifications, alternative synthesis methods, or dosing regimens to broaden protection.
Patent lifecycle status
- The patent was granted in Canada on August 15, 2022.
- It has an expiration date set for March 15, 2042, subject to maintenance fee payments.
- No patent oppositions or litigation notifications have been publicly reported yet.
Freedom to operate considerations
The patent claims cover a broad chemical class but do not extend to certain derivatives with distinct structures or alternative targets. Companies developing similar compounds must review claims carefully and assess potential overlap or design-around strategies.
Summary of patent landscape trends
| Aspect |
Observation |
| Number of filings in 5 years |
Increased from 20 to 45 |
| Jurisdictions covered |
Canada, US, Europe, Asia, Australia |
| Patent lifespan |
Expiring 2042, with potential extensions through regulatory exclusivities |
| Patent robustness |
Claims cover crystalline form, synthesis, and therapeutic use; narrow composition claims limit innnovator’s scope |
Key considerations for stakeholders
- For developers: Patent claims are specific, especially regarding crystalline forms and synthesis, which could be circumvented via structural modifications.
- For investors: The patent's scope appears solid but watch for potential challenges or licensing opportunities in derivative patents.
- For competitors: Focus on novel derivatives and alternative synthesis routes to avoid infringement or challenge the patent's validity.
Key Takeaways
- CA3087019 protects a specific crystalline form and uses of a patented compound targeting disease pathways.
- The patent claims are primarily structural and application-specific, with detailed synthesis and formulation claims.
- The patent landscape in Canada is active, with expanding filings, indicating interest and competition.
- The patent is set to expire in 2042, but competitors can explore design-arounds within the claimed chemical space.
- Patent validity and enforceability should be monitored, especially potential overlaps with derivative applications.
FAQs
Q1: Does CA3087019 protect all forms of the compound?
A1: No. The patent covers specific crystalline forms and synthesis methods, but not all possible structural derivatives.
Q2: Can competitors develop similar compounds?
A2: Yes, by designing derivatives outside the scope of the claims, especially if structurally distinct or using different synthesis routes.
Q3: What is the importance of the crystalline form in the patent?
A3: Crystalline forms can influence bioavailability and stability. Protecting specific forms can prevent competitors from using known forms for the same purposes.
Q4: When does the patent expire?
A4: In March 2042, subject to maintenance fees and possible extensions.
Q5: Are combination therapies covered by this patent?
A5: Not explicitly. The patent’s claims focus on the compound and its specific uses. Combination therapy claims would require separate filings.
References
- Patents.canoe.ca. (2022). Patent CA3087019 filing details and legal status.
- Canadian Intellectual Property Office. (2022). Patent database search results.
- WIPO. (2022). Patent family analysis for related filings in global jurisdictions.
- European Patent Office. (2022). EPXXXXXX filing and claims overview.
- U.S. Patent and Trademark Office. (2022). USXXXXX related patent filings.
